Adjuvant Treatment of Stage I–II Serous Endometrial Cancer: A Single Institution 20-Year Experience
Current Oncology · 2024
DOI: 10.3390/curroncol31070277 ↗Kurz gefasst
Fachartikel in der Zeitschrift Current Oncology, 2024. Verfasst von Aquila Akingbade und 4 weiteren Autor:innen. Beteiligte Einrichtung: Division of Radiation Oncology, London Health Sciences Center, Western University, London, ON N6A 5W9, Canada. Hauptthemen laut MEDLINE: Endometrial Neoplasms, Neoplasm Staging. Die Arbeit nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Canadian Association of Radiation Oncology–Canadian Radiation Oncology Foundation (CARO-CROF).
Abstract (Originalsprache)
Background
Serous endometrial carcinoma (SEC) is a high-risk subtype of endometrial cancer. The effectiveness of multiple adjuvant therapies, namely chemotherapy (CT), radiotherapy (RT), and sequential/concurrent chemotherapy with radiotherapy (CRT), have previously been investigated. However, optimal management of early-stage SEC remains unclarified.
Methods
All cases of early-stage SEC (FIGO 2009 stages I–II) treated in our institution from 2002 to 2019 were identified. Patient data were documented until September 2023. Overall survival (OS) and disease-free survival (DFS) were computed using Kaplan–Meier estimates and Cox’s proportional hazard model; descriptive statistical analysis was performed.
Results
A total of 50 patients underwent total hysterectomy-bilateral salpingo-oophorectomy and omentectomy, displaying stage IA (60%), IB (24%), and II (16%) disease. The median follow-up was 90.9 months. Patients underwent adjuvant CRT (n = 36, 72%), CT (n = 6, 12%), or RT (n = 6, 12%). Two patients were observed and excluded from analyses. The 42 patients who received radiotherapy had pelvic external beam radiotherapy (n = 10), vaginal brachytherapy (n = 21), or both (n = 11). CRT had better OS (HR 0.14, 95%CI 0.04–0.52, p < 0.005) and DFS (HR 0.25, 95%CI 0.07–0.97, p = 0.05) than CT alone. RT displayed no OS or DFS benefits compared to CT/CRT. Recurrences were mostly distant. Acute and late G3-4 toxicities were primarily hematologic.
Conclusions
Our data underline the challenge of treating SEC. CRT appears to be superior to CT alone but not to RT. Most recurrences were distant, highlighting the need for optimized systemic treatment options.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Radiation Oncology, London Health Sciences Center, Western University, London, ON N6A 5W9, Canada.
- Radiation Oncology Service, Centre Intégré de Cancérologie (CIC), Hôpital de l'Enfant-Jésus, Centre Hospitalier Universitaire de Québec, Québec, QC G1J 1Z4, Canada.
- Division of Radiation Oncology, McGill University Health Center, Montreal, QC H4A 3J1, Canada.
ORCID-Profile: Aquila Akingbade, Joanne Alfieri
Förderung
- Canadian Association of Radiation Oncology–Canadian Radiation Oncology Foundation (CARO-CROF)
Zitieren
APA
Akingbade, A., Fabi, F., Cartes, R., Tsui, J., & Alfieri, J. (2024). Adjuvant Treatment of Stage I–II Serous Endometrial Cancer: A Single Institution 20-Year Experience. Current Oncology. https://doi.org/10.3390/curroncol31070277
Vancouver
Akingbade A, Fabi F, Cartes R, Tsui J, Alfieri J. Adjuvant Treatment of Stage I–II Serous Endometrial Cancer: A Single Institution 20-Year Experience. Current Oncology. 2024. doi:10.3390/curroncol31070277
BibTeX
@article{Akingbade2024,
author = {Akingbade, Aquila and Fabi, François and Cartes, Rodrigo and Tsui, James and Alfieri, Joanne},
title = {Adjuvant Treatment of Stage I–II Serous Endometrial Cancer: A Single Institution 20-Year Experience},
journal = {Current Oncology},
year = {2024},
doi = {10.3390/curroncol31070277}
}
EUVIMED